Published in Curr Opin HIV AIDS on January 01, 2011
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis (2012) 1.29
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol (2011) 0.98
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther (2013) 0.93
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
Substance abuse, HIV-1 and hepatitis. Curr HIV Res (2012) 0.85
T memory stem cells and HIV: a long-term relationship. Curr HIV/AIDS Rep (2015) 0.84
Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol (2012) 0.84
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology (2013) 0.82
Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood (2013) 0.82
Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages. Biology (Basel) (2012) 0.80
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood (2011) 0.78
Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev (2016) 0.78
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
Hematopoietic stem cells and HIV infection. J Infect Dis (2013) 0.76
Early Antiretroviral Therapy is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. PLoS Pathog (2017) 0.75
Short communication: Colony-forming hematopoietic progenitor cells are not preferentially infected by HIV type 1 subtypes A and D in vivo. AIDS Res Hum Retroviruses (2012) 0.75
Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. Mol Ther Nucleic Acids (2015) 0.75
Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis. J Allergy Clin Immunol (2016) 0.75
Hepatitis B Virus Replication in CD34+ Hematopoietic Stem Cells From Umbilical Cord Blood. Med Sci Monit (2016) 0.75
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood (1997) 7.84
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Severe anemia in Malawian children. N Engl J Med (2008) 5.20
Adverse effects of antiretroviral therapy. Lancet (2000) 4.84
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature (1998) 2.82
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med (2010) 2.71
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science (1988) 2.55
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
The influence of human immunodeficiency virus-1 on hematopoiesis. Blood (1998) 2.15
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89
Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis (2008) 1.74
CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol (1992) 1.39
Profile of hematological abnormalities of Indian HIV infected individuals. BMC Blood Disord (2009) 1.39
Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa. Blood (2007) 1.28
Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest (1987) 1.24
Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol (1999) 1.23
HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog (2008) 1.22
Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol (2009) 1.19
Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood (1998) 1.19
Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood (2007) 1.17
CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood (1990) 1.15
Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol (1991) 1.10
Mast cell growth, differentiation, and death. Clin Rev Allergy Immunol (2002) 1.05
In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture. Blood (1995) 1.02
CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood (1995) 0.99
Haematological abnormalities associated with paediatric HIV/AIDS in Lagos. Ann Trop Paediatr (2006) 0.98
Human Mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro. J Virol (2001) 0.98
Anaemia in acute HIV-1 subtype C infection. PLoS One (2008) 0.96
Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals. Biol Blood Marrow Transplant (1999) 0.93
Immunodysregulation of HIV disease at bone marrow level. Autoimmun Rev (2005) 0.92
Bone marrow features in children with HIV infection and peripheral blood cytopenias. J Trop Pediatr (2005) 0.92
Impaired in vitro growth of purified (CD34+) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals. Blood (1992) 0.92
Mast cells: extended lifespan and lack of granule turnover under normal in vivo conditions. Exp Mol Pathol (1974) 0.91
Antigenic analysis of hematopoiesis: a review. J Hematother (1993) 0.89
Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART. Arch Virol (2010) 0.87
Effects of HIV type 1 infection on hematopoiesis in Botswana. AIDS Res Hum Retroviruses (2007) 0.87
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replication. AIDS (2006) 0.85
Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood (1996) 0.82
Failure to detect active virus replication in mast cells at various tissue sites of HIV patients by immunohistochemistry. Int J Biol Sci (2009) 0.81
Human immunodeficiency virus infection of human placental cord blood CD34+AC133+ stem cells and their progeny. AIDS Res Hum Retroviruses (1999) 0.81
IgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells. J Immunol (2009) 0.80
Defective HIV-1 provirus found in peripheral T lymphocytes and granulocytes in an AIDS patient imply viral infection of progenitor cells. AIDS (2001) 0.77
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med (2010) 2.71
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev (2006) 2.25
HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol (2004) 1.84
HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog (2008) 1.50
Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature (2010) 1.47
The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol (2011) 1.35
Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol (2003) 1.32
Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol (2002) 1.26
The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J Biol Chem (2007) 1.21
HIV-1 Nef disrupts antigen presentation early in the secretory pathway. J Biol Chem (2005) 1.12
HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements. J Virol (2011) 1.10
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
The emerging role of HLA-C in HIV-1 infection. Immunology (2011) 1.06
A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J Immunol (2008) 1.06
Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. Immunity (2003) 1.00
HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J Immunol (2006) 0.97
CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis (2013) 0.95
HIV immune evasion disruption of antigen presentation by the HIV Nef protein. Adv Virus Res (2011) 0.89
Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol (2013) 0.87
Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503. Immunogenetics (2009) 0.84
Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins. J Virol (2011) 0.83
Species-specific effects of HIV-1 Nef-mediated MHC-I downmodulation. Virology (2002) 0.83
Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells. Viruses (2012) 0.82
Interferon alfa therapy: toward an improved treatment for HIV infection. J Infect Dis (2012) 0.82
Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res (2010) 0.79
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79